GLG News by Physicians who Treat Multiple Myeloma (US)

Epo (J & J's version) increased mortality when given to patients with a new stroke in an effort to improve brain function. What will this lead too?? 

Costs for Medicare part D are going up 31%

Clinical trials are being built around determining which molecular profiles require what therapy. It's here!!

It will become public knowledge what Doctors are paid by Lilly for advice, lectures and other services.

Results are identicle (3 weeks v 5 in post lumpectomy radiation?)

Adoption of mandatory computerization will be gently forced on physicians and their offices

RNA gene profiling will allow up to get a better handle on the primary site, especially with increasing targeting opportunities in many neoplasms.

Proton beam therapy will effect the market place and force competition for oncology centers to get "the next best thing."

Velcade, given with Melphalan & Prednisone approved for use 1st line in non-transplant myeloma patients first line.

2 separate studies show that: 1. "...there was no statistically significant difference in overall survival....for gefitinib compared with docetaxel. Gefitinib remains an effective treatment option for previously treated Japanese patients with NSCLC." http://jco.ascopubs.org/cgi/content/full/26/26/4244...